Perrigo Confirms First To File Patent Challenge For Generic Version Of ProAir HFA Inhalation Aerosol
Perrigo Company (Nasdaq: PRGO) (NASDAQ: TASE) announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for albuterol sulfate HFA inhalation aerosol, the generic version of ProAir® HFA. The ANDA filing involved contributions from both Perrigo and Catalent Pharma Solutions, Inc., who partnered on the development of this project.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.